好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Logitudinal Effects of HOBSCOTCH - A Self-management Program for People with Epilepsy
Epilepsy/Clinical Neurophysiology (EEG)
S31 - Epilepsy/Clinical Neurophysiology (EEG) 3 (5:18 PM-5:30 PM)
010

To assess the longitudinal effects of the HOBSCOTCH epilepsy self-management program.

HOBSCOTCH (HOme-Based Self-management and COgnitive Training CHanges lives) is a behavioral intervention addressing cognitive dysfunction in adults with epilepsy. It has previously demonstrated efficacy in improving quality of life (QOL) and objective cognition. The current study presents longitudinal data from the multi-site, pragmatic replication trial.

Participants were block-randomized into three groups: in-person (HOB-IP, n=20), virtual treatment (HOB-V, n=17), or 6-month waitlist control (n=48). Participants were followed for 6-months after completing the 12-week intervention. Groups were compared on measures of QOL (QOLIE-31), objective cognition (BTACTm), and subjective cognition (NeuroQOL-Cognitive Function), collected every three months. 

This analysis focused on HOB-IP results. Differences between the in-person and virtual groups are discussed in another abstract.  HOB-IP showed significant improvements in QOL compared to controls (p<0.001) immediately post-intervention. Objective cognition remained unchanged, but self-reported cognitive function was improved following the intervention (p<0.001). At 3 months post-HOBSCOTCH, overall QOL scores dropped from a 12.4 point treatment effect to a 5.2 point effect, which was not statistically significant compared to controls (p=0.1). NeuroQOL scores dropped from a 6.2 treatment effect to a 2.4 point effect (p=0.13).

A within-group analysis tracked outcomes out to 6 months post-intervention. Statistically significant improvements were seen in both QOL (p=0.002) and subjective cognition (p<0.001) post-HOBSCOTCH compared to baseline. By 3 months post-treatment, subjective cognition scores were still improved (p=0.012), but overall QOL was not. At 6 months post, both outcome measures lost significance but remained elevated from baseline and appeared to stabilize.  

This is the first study to evaluate the longitudinal effects of HOBSCOTCH. While the intervention conveys significant short-term benefits, the effects diminished over time, suggesting that self-directed use of HOBSCOTCH was uncommon. Because the biggest drop in overall QOL occurred 3 months post-treatment, booster sessions may help sustain benefits.  

 

Authors/Disclosures

PRESENTER
No disclosure on file
Samantha Schmidt (Dartmouth-Hitchcock Medical Center) No disclosure on file
No disclosure on file
Lindsay Schommer, NP (Dartmouth) No disclosure on file
Felicia Chu, MD (Dept of Neurology, UMass Medical School) No disclosure on file
Heidi L. Henninger, MD, FAAN Dr. Henninger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB.
No disclosure on file
Elaine T. Kiriakopoulos, MD (Dartmouth-Hitchcock Medical Center) The institution of Dr. Kiriakopoulos has received research support from Centers for Disease Control and Prevention. The institution of Dr. Kiriakopoulos has received research support from Department of Defense. The institution of Dr. Kiriakopoulos has received research support from Epilepsy Foundation New England.
No disclosure on file
Barbara C. Jobst, MD, PhD, FAAN (Dartmouth-Hitchcock Med Ctr) Dr. Jobst has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. The institution of Dr. Jobst has received research support from Neuropace, Inc.. The institution of Dr. Jobst has received research support from Harvard Pilgrim. The institution of Dr. Jobst has received research support from NIH. The institution of Dr. Jobst has received research support from CDC.